SEC Form 4 · Rule 10b5-1 trading plans

MADRIGAL PHARMACEUTICALS, INC. (MDGL)

84Trades filed under a plan
5Plan adoption dates stated
8Quarterly results prints on file
0Trades in the days before a print

In the 2025 filing year, MADRIGAL PHARMACEUTICALS, INC. filed 13 Form 4 statements whose footnotes name a Rule 10b5-1 trading plan, by 6 reporting owners, covering 84 transactions filed under those plans and 296,208 shares. None carries the SEC's own AFF10B5ONE adoption flag; each of the 13 names a plan in a footnote. 8 results prints are on file in the same window, which is what makes the interval below measurable.

Trades filed under a plan in MADRIGAL PHARMACEUTICALS, INC. 84

Plan adoption dates stated in MADRIGAL PHARMACEUTICALS, INC. 5

Quarterly results prints on file in MADRIGAL PHARMACEUTICALS, INC. 8

Trades in the days before a print in MADRIGAL PHARMACEUTICALS, INC. 0

Interval to the next reported results date

For each transaction filed under a plan, the days between the transaction date and the company’s next results print. These are the dates the filings state, printed as an interval; the page draws no conclusion from them.

0Within 5 days of a print
0Within 10 days of a print
18Shortest interval, in days
0Trades with no later print on file

Adoption dates, as the filings state them

As the filings state it: “10b5-1 trading plan adopted by the Reporting Person on March 14, 2025”

Reported results dates on file

A proxy statement is on file for this company in the same window, which is where a company states its own trading policy.

Other companies with plan records

Order the document

Every company with plan records →

Form 4 statements and their footnotes from the SEC’s EDGAR full-text search, and this company’s results dates, industry classification and state of incorporation from the SEC submissions API. The page prints the dates the filings state and the interval between them; it draws no conclusion from them.